Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $511.5 million.

  • PROCEPT BioRobotics' Liabilities and Shareholders Equity rose 3672.38% to $511.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 billion, marking a year-over-year increase of 3527.6%. This contributed to the annual value of $534.0 million for FY2024, which is 3194.83% up from last year.
  • Latest data reveals that PROCEPT BioRobotics reported Liabilities and Shareholders Equity of $511.5 million as of Q3 2025, which was up 3672.38% from $513.1 million recorded in Q2 2025.
  • PROCEPT BioRobotics' 5-year Liabilities and Shareholders Equity high stood at $534.0 million for Q4 2024, and its period low was $272.4 million during Q2 2023.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $374.1 million (2024), whereas its average is $385.0 million.
  • As far as peak fluctuations go, PROCEPT BioRobotics' Liabilities and Shareholders Equity skyrocketed by 16754.09% in 2021, and later tumbled by 1237.62% in 2023.
  • PROCEPT BioRobotics' Liabilities and Shareholders Equity (Quarter) stood at $337.0 million in 2021, then decreased by 8.22% to $309.3 million in 2022, then soared by 30.84% to $404.7 million in 2023, then soared by 31.95% to $534.0 million in 2024, then decreased by 4.21% to $511.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $511.5 million in Q3 2025, compared to $513.1 million in Q2 2025 and $519.4 million in Q1 2025.